welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.
The ideal treatment for thyroid eye disease would decrease inflammation, reduce proptosis and double vision, improve quality of life, have minimal adverse effects and minimize the need for surgical treatment, Raymond S. Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, said in a presentation on the topic at Hawaiian Eye 2020.
Additionally, this treatment would target the long-term manifestations of the disease rather than the short-term manifestations that are primarily targeted with steroids and other second line agents, he said.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
Preoperative Clinical Features of Reactivated of Graves’ Orbitopathy After Orbital DecompressionPurpose: To investigate the incidence a...
Clinical Implications of Immunoglobulin G4 to Graves’ OphthalmopathyBackground: This study aimed to explore...
Management of Graves Thyroidal and Extrathyroidal Disease: An UpdateContext: Invited update on the manageme...
Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye DiseasePurpose: To present an update on the ef...
Wills Eye HospitalWills Eye Hospital, located in Philadelp...
Bascom Palmer Eye InstituteBascom Palmer Eye Institute, part of the...
James A. Garrity, MDDr. James Garrity is an ophthalmologist ...